{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T10:56:35Z","timestamp":1752231395432,"version":"3.41.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Levamisole is used as a steroid-sparing drug for the treatment of frequently relapsing or steroid-dependent idiopathic nephrotic syndrome in children. As part of a large multicentre randomized controlled trial with levamisole, pharmacokinetic and pharmacodynamic parameters of levamisole in children with idiopathic nephrotic syndrome were investigated, as well as the feasibility of using saliva as an alternative and patient-friendly matrix for determining levamisole concentrations. In this study, the authors presented the development and validation of a highly sensitive method for determining levamisole in plasma and saliva using liquid chromatography-tandem mass spectrometry (LC-MS\/MS).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>In 100 \u03bcL samples, proteins were precipitated with 750 \u03bcL acetonitrile\/methanol 420:80 (v\/v) with levamisole-D5 as an internal standard. Calibration standards were prepared over a range of 0.1 ng\/mL\u201350 ng\/mL. To determine ultrafiltration efficiency, the ultrafiltrate was obtained by centrifuging blank plasma samples over the filter. Both filtered and nonfiltered samples were analyzed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>For plasma, accuracy and within-run and between-run imprecision were between 95.0% and 100% and &lt;14.5%, respectively, and for saliva, between 100.9% and 107.5%, and &lt;13.3%. No significant matrix effects were observed. Samples were stable at benchtop for 24 hours and \u221280\u00b0C, for at least 14 months (stability experiments ongoing). The ultrafiltration efficiency of unbound concentrations in plasma was lower than 85% (58.9%) but stable, and, therefore, the observed concentration should be corrected.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Based on observations, the developed measure can determine levamisole concentrations in participant saliva samples.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000000811","type":"journal-article","created":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T22:50:35Z","timestamp":1599691835000},"page":"279-285","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Development and Validation of a Highly Sensitive Liquid Chromatography-Tandem Mass Spectrometry Technique to Determine Levamisole in Plasma and Saliva"],"prefix":"10.1097","volume":"43","author":[{"given":"Floor","family":"Veltkamp","sequence":"first","affiliation":[{"name":"Pediatric Nephrology, and"},{"name":"Pharmacy, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcel C. M.","family":"Pistorius","sequence":"additional","affiliation":[{"name":"Pharmacy, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonia H. M.","family":"Bouts","sequence":"additional","affiliation":[{"name":"Pediatric Nephrology, and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron A. A.","family":"Math\u00f4t","sequence":"additional","affiliation":[{"name":"Pharmacy, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the LEARNS consortium","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s00467-004-1615-9","article-title":"Levamisole in steroid-sensitive nephrotic syndrome of childhood: the lost paradise?","volume":"20","author":"Davin","year":"2005","journal-title":"Pediatr Nephrol"},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"860","DOI":"10.3390\/jcm8060860","article-title":"Levamisole in children with idiopathic nephrotic syndrome: clinical efficacy and pathophysiological aspects","volume":"8","author":"M\u00fchlig","year":"2019","journal-title":"J Clin Med"},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.kint.2017.08.011","article-title":"A randomized clinical trial indicates that levamisole increases the time to relapse in children with steroid-sensitive idiopathic nephrotic syndrome","volume":"93","author":"Gruppen","year":"2018","journal-title":"Kidney Int"},{"key":"R4-20250603","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1007\/s11255-012-0241-x","article-title":"Short- and long-term efficacy of levamisole in children with steroid-sensitive nephrotic syndrome","volume":"45","author":"Elmas","year":"2013","journal-title":"Int Urol Nephrol"},{"key":"R5-20250603","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s00467-017-3616-5","article-title":"Efficacy of higher-dose levamisole in maintaining remission in steroid-dependant nephrotic syndrome","volume":"32","author":"Abeyagunawardena","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"R6-20250603","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/j.1365-2249.2007.03541.x","article-title":"Levamisole enhances immune response by affecting the activation and maturation of human monocyte-derived dendritic cells","volume":"151","author":"Chen","year":"2008","journal-title":"Clin Exp Immunol"},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1046\/j.1365-2567.2000.00042.x","article-title":"Levamisole induces interleukin-18 and shifts type 1\/type 2 cytokine balance","volume":"100","author":"Szeto","year":"2000","journal-title":"Immunology"},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/bcp.12607","article-title":"Population pharmacokinetics of levamisole in children with steroid-sensitive nephrotic syndrome","volume":"80","author":"Kreeftmeijer-Vegter","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0378-4347(00)00171-7","article-title":"Quantitative analysis of levamisole in porcine tissues by high-performance liquid chromatography combined with atmospheric pressure chemical ionization mass spectrometry","volume":"742","author":"Cherlet","year":"2000","journal-title":"J Chromatogr B"},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jchromb.2010.11.015","article-title":"A sensitive LC-MS\/MS method for determination of levamisole in human plasma: application to pharmacokinetic study","volume":"879","author":"Tong","year":"2011","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0378-4347(00)80120-6","article-title":"Ion-pair high-performance liquid chromatographic assay of levamisole in biological fluids","volume":"223","author":"Alvinerie","year":"1981","journal-title":"J Chromatogr."},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF03226369","article-title":"Quantitation of levamisole in plasma using high performance liquid chromatography","volume":"20","author":"Vandamme","year":"1995","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"R13-20250603","first-page":"954","article-title":"Gas-liquid chromatographic determination of levamisole residues in bovine milk","volume":"59","author":"Smith","year":"1976","journal-title":"J Assoc Off Anal Chem."},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/BF03189527","article-title":"Gas-chromatographic determination of levamisole in human plasma-normalization and reliability of the method","volume":"6","author":"Rousseau","year":"1981","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1039\/an9800500993","article-title":"Determination of the anthelmintic levamisole in plasma and gastro-intestinal fluids by high-performance liquid chromatography","volume":"105","author":"Marriner","year":"1980","journal-title":"Analyst"},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1080\/02652039809374660","article-title":"A highly sensitive gas chromatographic determination of levamisole in milk","volume":"15","author":"Schenck","year":"1998","journal-title":"Food Addit Contam"},{"key":"R17-20250603","doi-asserted-by":"crossref","first-page":"e027011","DOI":"10.1136\/bmjopen-2018-027011","article-title":"Prevention of relapses with levamisole as adjuvant therapy in children with a first episode of idiopathic nephrotic syndrome: study protocol for a double blind, randomised placebo-controlled trial (the LEARNS study)","volume":"9","author":"Veltkamp","year":"2019","journal-title":"BMJ Open"},{"key":"R20-20250603","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s00216-006-0581-4","article-title":"Validation and qualification: the fitness for purpose of mass spectrometry-based analytical methods and analytical systems","volume":"386","author":"Careri","year":"2006","journal-title":"Anal Bioanal Chem"},{"key":"R21-20250603","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.clinbiochem.2004.11.007","article-title":"Matrix effects: the Achilles heel of quantitative high-performance liquid chromatography-electrospray-tandem mass spectrometry","volume":"38","author":"Taylor","year":"2005","journal-title":"Clin Biochem"},{"key":"R22-20250603","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1021\/ac020361s","article-title":"Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS\/MS","volume":"75","author":"Matuszewski","year":"2003","journal-title":"Anal Chem"},{"key":"R23-20250603","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.nephro.2005.06.003","article-title":"Syndrome n\u00e9phrotique pur (ou n\u00e9phrose) corticosensible de l'enfant: protocole de traitement propos\u00e9 par la Soci\u00e9t\u00e9 de N\u00e9phrologie P\u00e9diatrique","volume":"1","author":"B\u00e9rard","year":"2005","journal-title":"Nephrol Ther"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000811","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:29:08Z","timestamp":1748971748000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000000811"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000000811","relation":{},"ISSN":["0163-4356"],"issn-type":[{"type":"print","value":"0163-4356"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"2020-06-13","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}